Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond

7Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Prostate-specific membrane antigen (PSMA) imaging is characterized by superior accuracy compared to conventional imaging for identification of nodal and distant metastases in prostate cancer. The majority of international clinical guidelines recommend PSMA positron emission tomography/computed tomography for patients experiencing biochemical recurrence, even at low prostate-specific antigen values, to identify candidates for salvage therapies. However, its use in for primary staging is still not recommended.

Cite

CITATION STYLE

APA

Gandaglia, G., Leni, R., Fossati, N., Cucchiara, V., Montorsi, F., & Briganti, A. (2021, March 1). Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond. European Urology Focus. Elsevier B.V. https://doi.org/10.1016/j.euf.2020.12.014

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free